You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Central Nervous System Lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Micro and Macroscopic Level of Primary Central Nervous System

Active, not recruiting
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Tumor samples and MRI
  • Paris, France
    Groupe Hospitalier La Pitié Salpêtrière
Feb 17, 2022

Primary CNS Lymphoma Trial in Paris (Rituximab, Methotrexate, Temozolomide)

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Rituximab, Methotrexate, Temozolomide
  • Paris, France
    Groupe Hospitalier Pitie Salpetriere
Feb 10, 2022

Lymphoma, Non-Hodgkin, CNS Tumors Trial in Trondheim (18F-FDG, 18F-fluciclovine, standard MRI)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Central Nervous System Neoplasms
  • 18F-FDG
  • +2 more
  • Trondheim, Norway
    Norwegian University of Science and Technology, Department of Ci
Dec 15, 2021

Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)

Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
Jul 27, 2022

Patients With Suspected or Diagnosed CNS Lymphoma Trial in Seoul ([18F]FET)

Recruiting
  • Patients With Suspected or Diagnosed Central Nervous System Lymphoma
  • Seoul, Songpa-Gu, Korea, Republic of
    Asan Medical Center
Oct 7, 2021

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • DISEASE
  • (no location specified)
May 4, 2023

CNS Lymphoma Trial in Worldwide (GB5121)

Recruiting
  • CNS Lymphoma
  • Phoenix, Arizona
  • +5 more
Jul 26, 2022

CNS Lymphoma Trial in Essen ([90Y]Y-PentixaTher)

Recruiting
  • CNS Lymphoma
  • Essen, Germany
    University Hospital Essen
Nov 16, 2023

Lymphoma, Large B-Cell, Diffuse Trial in Milan (NGR-hTNF, RITUXIMAB, Doxorubicin)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Milan, Italy
    Ospedale San Raffaele
Aug 2, 2022

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    Primary CNS Lymphoma Trial in Stuttgart (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix,

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
    • Control intervention: four courses of MATRix
    • Stuttgart, Baden-Württemberg, Germany
      Klinikum Stuttgart
    Feb 15, 2022

    Lymphoma, Large B-Cell, Diffuse, CNS Tumors, Primary Trial in France (Lenalidomide, Ibrutinib)

    Recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • Central Nervous System Neoplasms, Primary
    • Amiens, France
    • +26 more
    Nov 30, 2022

    CNS B-Cell Non-Hodgkin Lymphoma Trial in United States (procedure, biological, other)

    Recruiting
    • Central Nervous System B-Cell Non-Hodgkin Lymphoma
    • Cognitive Assessment
    • +2 more
    • Denver, Colorado
    • +11 more
    Jun 9, 2022

    Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • +2 more
    • Guandong, Guangdong, China
    • +2 more
    Apr 6, 2022

    Primary CNS Lymphoma Trial in Milan (Lumbar puncture)

    Recruiting
    • Primary CNS Lymphoma
    • Lumbar puncture
    • Milan, Italy/Lombardy, Italy
      IRCCS Ospedale San Raffaele
    Sep 5, 2021

    Primary CNS Lymphoma Trial in Beijing (orelabrutinib, Sintilimab, Tislelizumab)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Beijing, Beijing, China
      Wei Zhang
    May 19, 2021

    Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

    Suspended
    • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
    • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 6, 2022

    Lymphoma, Lymphoma Cns Trial in Boston (Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel)

    Recruiting
    • Lymphoma
    • Lymphoma Cns
    • Boston, Massachusetts
    • +1 more
    Jan 3, 2023

    Primary CNS Lymphoma Trial in Paris ([18F]-FDG PET/MR)

    Active, not recruiting
    • Primary Central Nervous System Lymphoma
    • [18F]-FDG PET/MR
    • Paris, France
      Pitié Salpêtrière Hospital
    Sep 9, 2021

    Part A: Relapsed or Refractory Primary CNS Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL Trial in United

    Recruiting
    • Part A: Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL
    • Duarte, California
    • +29 more
    Jun 15, 2022

    CNS Lymphoma Trial in Duarte (procedure, biological, drug)

    Recruiting
    • Central Nervous System Lymphoma
    • Aspiration
    • +10 more
    • Duarte, California
      City of Hope Medical Center
    Dec 8, 2022

    Primary CNS Lymphoma Trial in Worldwide (Rituximab, Methotrexate, Procarbazine)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Aarhus, Denmark
    • +34 more
    Nov 4, 2022

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +7 more
    • Manchester, United Kingdom
    • +2 more
    Aug 11, 2022

    PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

    Not yet recruiting
    • PCNSL
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Jun 8, 2023

    TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System

    Completed
    • Lymphoma, B-Cell
      • Montpellier, France
        Uh Montpellier
      Nov 12, 2021